From John Money to Modern Gender Clinics: An Insider Speaks - Dr. Quentin Van Meter (#28)
A paediatric endocrinologist with forty years of clinical experience, Dr. Quentin Van Meter was present at the birth of modern gender medicine — training alongside John Money at Johns Hopkins and watching WPATH evolve into what he considers a scientifically unfounded advocacy body. His insider account, covering everything from puberty-blocker risks to his eventual departure from the American Academy of Pediatrics, carries particular weight for European countries that built their gender-medicine frameworks on WPATH guidelines and are now urgently revising them.
When Dr. Quentin Van Meter treated his first gender-distressed child in 1993, there were no clinical guidelines to consult. Over four decades of paediatric endocrinology, he watched a specialist field take shape — one that, in his assessment, increasingly substituted ideological commitment for rigorous science. This episode gives him space to trace how that happened, beginning with a first-hand account of working alongside John Money during a fellowship at Johns Hopkins. Money's contribution — separating gender identity from biological sex — underpins virtually every clinical protocol that followed, and Van Meter recalls witnessing practices there that he describes as ethically indefensible, including a proposal to castrate an infant whose testosterone levels were entirely normal. Van Meter's most direct challenge is to the World Professional Association for Transgender Health. He describes WPATH as having drifted from a professional medical body into something closer to an advocacy organisation, its published standards resting, in his view, on what he characterises as scientific trash. For European countries that built their paediatric gender services on WPATH frameworks — among them Sweden, Finland, the Netherlands, Germany and France — that verdict from a senior clinician with four decades in the field is not easily set aside. Several of those countries have already opened formal reviews of their paediatric gender services, and insider testimony of this kind sharpens the questions those reviews must answer. Two specific claims are likely to draw the most attention from European clinicians and policymakers. Van Meter cites evidence suggesting that close to ninety-eight per cent of children placed on puberty blockers go on to receive cross-sex hormones, undermining the argument that blockers function as a cautious pause before any irreversible intervention. He also raises research linking prolonged GnRH analogue use with increased dementia risk — a concern that, if it holds under scrutiny, places the long-term cognitive safety of these treatments in serious doubt. Both points reinforce the scepticism about the evidence base for paediatric gender medicine that has emerged from independent reviews across northern Europe. For continental European listeners, the episode offers something that domestic policy debates rarely provide: the perspective of a senior clinician who was present at the creation of modern gender medicine and has spent decades contesting it from within the profession. Van Meter's eventual resignation from the American Academy of Pediatrics — over what he describes as a fabricated institutional policy on transgender care — is a reminder that pressure to conform is not unique to any one country or health system. Sweden and Finland have curtailed paediatric gender medicine on evidential grounds; England has followed. The question this episode poses for Germany, France and the Netherlands is how similar reconsiderations can continue to be deferred when the foundational evidence is under such sustained challenge from those who helped construct it. Beyond Gender gives Van Meter space to develop arguments that most professional bodies have been reluctant to engage with publicly. His four decades of clinical experience, combined with direct knowledge of how this field originated, make him a witness whose account demands serious consideration from anyone involved in shaping paediatric gender policy across Europe.
